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Toll-like receptors (TLRs) are important sentinels of bacterial and viral infection and thus fulfil a critical 
sensory role in innate immunity. Polo-like kinases (PLKs), a five membered family of Ser/Thr protein 
kinases, have long been studied for their role in mitosis and thus represent attractive therapeutic 
targets in cancer therapy. Recently, pLKs were implicated in tLR signaling in mice but the role of 
pLKs in tLR signaling in untransformed primary immune cells has not been addressed, even though 
PLK inhibitors are in clinical trials. We here identified several phospho-serine and phospho-threonine 
residues in the known TLR pathway kinases, Interleukin-1 receptor-associated kinase (IRAK) 2 and 
IRAK4. These sites lie in canonical polo-box motifs (PBM), sequence motifs known to direct recruitment 
of PLKs to client proteins. Interestingly, PLK1 was phosphorylated and PLK 2 and 3 mRNA induced 
upon tLR stimulation in primary immune cells, respectively. in whole blood, pLK inhibition disparately 
affected TLR mediated cytokine responses in a donor- and inhibitor-dependent fashion. Collectively, 
pLKs may thus potentially interface with tLR signaling in humans. We propose that temporary pLK 
inhibitor-mediated blockade of tLR-signaling in certain patients receiving such inhibitors during cancer 
treatment may cause adverse effects such as an increased risk of infections due to a then compromised 
ability of the tLR recognition system to sense and initiate cytokine responses to invading microbes.
Toll-like receptors (TLRs) are important pattern recognition receptors (PRR) of the innate immune system. In 
this capacity, TLRs recognize different microbe-associated molecular patterns (MAMPs) but also sense endog-
enous danger-associated molecular patterns (DAMPs)1. Upon activation, TLR signals are integrated and diver-
sified intracellularly by adaptor molecules, one of which is MyD881. Apart from NF-κB, MyD88-dependent 
signaling is able to activate MAP kinases, interferon regulatory factors (IRFs)1,2, and the PI(3) kinase pathway3. 
Through gene transcriptional programs regulated by these pathways important innate immune functions, such 
as cytokine response or costimulatory molecule expression, are shaped. In humans and mice, four Interleukin-1 
receptor (IL-1R)-associated kinase (IRAK) family members, IRAKs 1–4, with non-redundant functions, expres-
sion patterns and effector preferences (e.g. early vs late cytokine regulation) are involved in MyD88-dependent 
downstream signaling2,4. IRAKs feature an N-terminal death domain (DD) engaging upstream MyD88 within 
the so-called Myddosome, an oligomeric post-receptor complex hierarchically assembled via MyD88, IRAK4 and 
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IRAK2 DD protein-protein interactions5. Work by us and others showed that naturally occurring loss-of-function 
mutations in MyD88 prevent Myddosome formation6 and suggest that the Myddosome is a critical post-receptor 
complex in innate immunity7. The IRAK kinase domain (KD) activity is switched on first in IRAK4 then IRAK1 
or 2 upon Myddosome formation and initiates the subsequent steps of downstream signaling such as the ubiq-
uitination of TNF receptor-associated factor (TRAF) 6. TRAF6 ubiquitination is sensed by the ubiquitin binding 
regulatory TAB2/TAB3 subunits of the TAK1 complex which subsequently initiates MAPK and IKKα/β acti-
vation8. One hallmark of the multi-faceted gene transcription programs regulated by the transcription factors 
activated by MAPK and IKK, namely AP-1 and NF-κB, is the production of pro-inflammatory cytokines. In some 
cell types, predominantly plasmacytoid dendritic cells (pDC), MyD88-IRAK-dependent signaling activates IFN 
regulatory factors (IRF) which are important for type I IFN induction. Thus through triggering expression of 
pro-inflammatory cytokines such as IFNs, TLRs shape courses of infections1. Recent data also point to an involve-
ment of MyD88-dependent signaling in the context of non-Hodgkin lymphomas, where MYD88 gain-of-function 
mutations promote tumor cell growth9. Thus it is of interest to characterize modulators of these signaling events 
for therapeutic intervention.
Recently an intriguing link between TLR signaling and Polo-like kinases (PLKs) was reported10. The human 
PLK family includes five members, PLK1-5. Especially PLK1 has been extensively studied in the context of cell 
cycle regulation. In cell cycle regulation, PLK1 cooperates with cyclin-1 dependent kinase 1, cyclin B1 and Aurora 
kinase and is involved in centrosome maturation, G2/M transition, kinetochore function, mitotic exit and cytoki-
nesis. The roles of other PLKs are more enigmatic but implication as tumor suppressors by interaction with the 
p53 signaling network have been proposed. PLKs canonically consist of an N-terminal KD and a C-terminal 
so-called Polo-box domain (PBD)11. It is believed that the PBD directs PLKs to substrate molecules by binding to 
conserved so-called Polo box motif (PBM), typically comprised of Ser-pThr-Pro or Ser-pSer-Pro (SpSP/SpTP)12. 
Binding of the PBD to PBM sequences is then thought to relieve PLK KD inhibition and activate PLK kinase 
activity. In the context of cell division, many PBM-containing PLK binding partners have been described and 
proteomics screens identified >600 proteins that interact with PLK1. In the context of cell division, PBM motifs 
are “generated” through phosphorylation of SSP and STP sequences by cyclin-dependent kinases (CDKs)13. Their 
essential requirement in cell division has given rise to the notion that PLKs constitute attractive targets for cancer 
therapy (see ref.14 and www.clinicaltrial.gov). Inhibition of PLKs resulted in an abortive cell cycle and drive cancer 
cells into apoptosis14. Inhibitors such as BI2536, BI6727 (Volasertib) and GSK461364 have been reported to pos-
sess nanomolar IC50 values and target PLK1 KD activity14. Fewer approaches have targeted the PBD of PLK1, for 
example poloxin14. The specificity of PBD-targeting inhibitors for PLK1 varies but most inhibitors also affect other 
PLKs, so that the efficacy of PLK1 inhibitors could at least partially result from additional effects on other PLKs, 
e.g. PLKs 2 to 4 for which off-target effects of PLK1 inhibitors were reported14. Several published academia- and 
industry-driven phase I and II clinical studies using the abovementioned compounds so far show good tolerabil-
ity, limited side-effects and promising results in terms of efficacy in non-small cell lung cancer and non-Hodgkin 
lymphoma15–17. Thus PLK inhibitors may be licensed for use in humans at some stage in the near future.
Unfortunately, possibly due to the fact that homozygous PLK1 mice are not viable, relatively little is known 
about the role of PLK1 in processes other than cell cycle regulation. The same applies to other PLKs. However, 
a recent report by Chevrier et al. identified PLK2 and 4 in an siRNA screen to be involved in TLR signaling in 
murine cells and PLK1 inhibitors recapitulated the effects observed by PLK2 and 4 knock-down10. Specifically, 
BI2536 blocked transcription of antiviral genes such as Ifnb1, Cxcl10 and Cxcl1. Unfortunately, the situation in 
human primary immune cells was not addressed. Other groups reported that PLK1 interacted with NEMO (also 
known as IKKγ) via the scaffold protein TANK (also known as TRAF2) affecting NF-κB signaling in HEK293 
and K562 cell lines18. Additionally, TANK and IKKβ were found to be phosphorylated by PLK1 in proteomics 
approaches analyzing samples from Hela or COS7 and HEK293 cell lines, respectively19,20. It is unknown which 
upstream signal(s) prompt(s) the recruitment and/or kinase activity of PLK1 in this context and by which mecha-
nism. Prolyl isomerase (PIN) 1 is another substrate and interactor of PLK1 in Hela cells19. PIN1 also interacts with 
murine IRAK1, and this interaction was dependent on phosphorylation sites in the IRAK1 linker region (S131, 
S144, S173)21. Thus PIN1 may act as a bridging molecule between IRAKs and PLKs. On the other hand, PLKs 
and IRAKs may counter-influence each other through direct interactions although this has not been proven. 
Collectively, there is some reported evidence for a role of PLKs in several innate immune signaling pathways. 
However, all of the above reported data in human cells were exclusively generated using immortalized cell lines 
and thus may potentially be confounded by continuous PLK activation during cell division. Studies using primary 
cells have so far only been conducted in murine cells10. Therefore it is unclear if PLKs do in fact play a role in 
human primary immune cells.
After identifying PBMs in members of the IRAK family, we sought to gather evidence for a link between PLKs 
andTLR mediated responses. Here we report the presence of Polo-box-motifs (PBMs) in human IRAK2 and 
IRAK4 which would enable a mechanistic link between TLR-MyD88-IRAK signaling and PLKs. PLK1 was phos-
phorylated upon TLR stimulation and PLK2 and 3 gene transcription was found to be upregulated in primary 
human cells. Additionally, we report that PLK inhibitors may interfere with TLR-mediated cytokine production 
in whole blood in a donor-dependent way.
Results
Human IRAK2 and IRAK4 harbor Polo-box motifs. In a search for regulatory events in TLR path-
ways, we investigated phosphorylation sites in the human IRAKs and identified phospho- serine 144 (S144) 
by mass spectrometry of recombinant IRAK2 protein purified from mammalian cells (HEK293T) (Fig. 1A,B). 
S144 maps to the linker region between the IRAK2 DD and KD (red box in Fig. 1A). The sequence of this linker 
region is not related to linker regions of the other three IRAK orthologues. Furthermore S144 of IRAK2 is only 
present in homologues from humans and primates but not in mice. We could also identify several probable 
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auto-phosphorylation sites in IRAK4 after it was purified from E. coli, using a buffer composition and ATP con-
centration that are conducive to the recombinant protein developing kinase activity. This IRAK4 protein was 
subjected to tryptic digest and analyzed by mass spectrometry(MS). More than 20 new phospho-sites were iden-
tified (Fig. 1C) and two of these (S8, T62) when mutated affected the interaction of IRAK4 with MyD88 as shown 
elsewhere22. The newly identified phospho-sites included S152 (red box in Fig. 1C). When inspecting these sites 
more closely, we noted that pS144 in IRAK2 and pS152 in IRAK4 are part of hitherto unrecognized PBMs, both 
SpSP (red boxes in Fig. 1A,C). Interestingly, both phospho-sites map to the linker regions connecting DD and KD 
the structural conformation of which regulates activity in murine Irak121. Primary sequence analysis identified 
several additional putative PBMs in human IRAKs: in IRAK1 residues 399–401 (S400 is also phosphorylated, not 
shown); and in the IRAK2 KD at position 275–277 (phosphorylation status of S276 unknown to date, Fig. 1C). 
To gain a first insight into whether these sites are phosphorylated and possibly regulated in immune cells, we 
stimulated THP-1 macrophage-like cells with the TLR2 ligand, Pam2CSK4, a synthetic deacetylated lipopeptide 
(here referred to as Pam2), for 30 min and conducted a preliminary phospho-proteomics experiment, analyzing 
Figure 1. IRAK2 and 4 contain novel phospho-sites that map to Polo-box motifs. (A) Overview of human 
IRAK2 primary sequence (yellow) with DD and KD indicated in dark grey. Putative PBM are in blue with red 
boxes, and the newly identified phospho-S144 highlighted. (B) MS-MS fragment spectrum for the IRAK2 
135–147 tryptic fragment containing the S144 phosphorylation (red). (C) as in A but shown for human IRAK4. 
Already published sites are shown in blue, sites newly identified in this study in red. S152 is highlighted.
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changes in phospho-peptides concerning IRAK1, 2 and 4. Pam2 was chosen as it had previously been shown 
to affected the phospho-status of IRAK1 S40223. As shown in Table 1, IRAK1 phospho-peptides encompassing 
S399, S401 and S402 (and thus the PBM) were identified, in agreement with independent crystallographic and 
proteomics evidence24,25. In stimulated THP-1 cells the sites changed their abundance between 1,8 to >10-fold 
following Pam2 stimulation compared to unstimulated cells. For IRAK2, a peptide encompassing S143 and S144 
was detected. Even though S143 was downregulated approx. 5-fold upon stimulation, S144 was unaltered, indi-
cating it might be a constitutive, not ligand-dependent PBM. IRAK4 S186, T208 and T345 were also confirmed as 
phospho-residues but not the putative PBM residue S152. The latter was, however, reported in a comprehensive 
database of phospho-sites, phospho-site.org, in 5 studies that included human primary cellular material25–29. 
Phospho-site.org generally confirmed all PBM sites described here for IRAKs, except S275 in IRAK2 and S186 in 
IRAK4, see Table 1. The data from THP-1 cells and comprehensive independent evidence from other studies23–38 
thus suggest that some, if not all, phospho-sites detected here on overexpressed IRAKs in PBMs are potentially 
physiologically relevant. Since PBMs had not been noted in IRAKs before and the role of Polo kinases in TLR 
signaling in human primary cells has not been addressed, we took these findings as a starting point for experi-
mentally exploring a possible connection between PLKs and TLR signaling.
pLKs are transcribed upon tLR stimulation. Since many TLR pathway signal transducers such as 
MyD88 are themselves regulated by TLR signaling, we tested whether PLKs were also regulated at the mRNA 
level in whole blood. Figure 2 shows that treatment of freshly drawn human whole blood with the TLR7/8 agonist 
R848 or the TLR4 agonist LPS induced cellular PLK2 and PLK3 mRNA levels by approximately 20-fold or 10-fold 
within 2 h, respectively. For PLK3, mRNA induction remained high up to 6 h whereas PLK2 induction decreased 
by 6 h. PLK1 and PLK4 were not induced by TLR stimulation. Likewise the TLR3 ligand poly I:C and IL-1 did not 
induce PLK transcription. This suggests that PLKs may be part of a TLR-elicited feed-forward loop relevant for 
effector outcomes or to anticipate cellular proliferation.
PLK1 is phosphorylated upon TLR stimulation. We next sought to determine whether PLKs are 
directly activated in response to TLR signaling as well as being transcriptionally upregulated. During mitosis, 
phosphorylation of PLKs is an indicator of activation39. Since there are currently no phospho-specific antibodies 
for the highly regulated PLKs 2 or 3, we focused on the modification of PLK1 as a representative of the PLK family 
that has been widely characterized and for which phospho-specific antibodies are available. Whole blood was thus 
analyzed by anti-phospho-Thr210 flow cytometry40 after 10 min of R848 stimulation. Figure 3 shows that PLK1 
was phosphorylated in gated monocytes, lymphocytes (PBL) and neutrophils (PMN), with monocytes showing 
the greatest differences in MFI for all donors (n = 3, Fig. 3b). Although further mechanistic details remain to be 
elucidated, these data suggest that at least PLK1 is activated by TLR triggering and may thus contribute to TLR 
signal transduction by kinase activity or scaffolding function.
Inhibition of PLK in human primary immune cells disparately affects cytokine induction. The 
data so far suggested that PLKs are regulated duringTLR signaling. If indeed this was the case, PLK inhibition 
may affect TLR mediated cytokine transcription. Given the reported observation for a role of PLK in murine 
innate immune responses, we sought to test if pharmacological inhibition of PLK kinase activity using BI2536, 
BI6727 or GSK46136441 affected the induction of cytokines in response to R848. As shown in Fig. 4, stimulation 
Gene 
names
Protein 
Uniprot ID
Position 
in peptide 
sequence
Localization 
probability PEP
Number 
Phospho-
STY sites
Amino 
acid
Sequence and Phospho (STY) 
Probabilities
Position 
in peptide Charge
Mass 
error 
[ppm]
Ratio 
treatment/
untreated
Listed in 
phospho-site.
org?
IRAK1 D3YTB5-1 399 0,82 1.92E-13 1 S FAGSS(0.004)PS(0.816)QS(0.144)S(0.035)MVAR 7 2 −16,24 1,86 YES (S373)
24
IRAK1 D3YTB5-1 401 0,90 3.24E-40 1 S FAGSSPS(0.002)QS(0.902)S(0.095)MVAR 9 2 −17,26 13,30 YES (S375)
24,25
IRAK1 D3YTB5-1 402 0,88 2.56E-62 1 S FAGSSPS(0.002)QS(0.114)S(0.883)MVAR 10 2 −0,41 11,71 YES (S376)
23–25
IRAK1 D3YTB5-1 413 0,73 0,000344 2 T TQTVRGT(0.726)LAY(0.637)LPEEY(0.637)IK 7 2 -0,63 0,48
YES 
(T387)23,24,37,38
IRAK2 O43187 143 0,70 2.15E-14 1 S MATFPGPGS(0.696)S(0.304)PAR 9 2 0,11 0,24 YES (S143)
31
IRAK2 O43187 144 0,50 0,00182 S MATFPGPGS(0.5)S(0.5)PAR 10 2 33,36 n/a YES (S144)25,30
IRAK4 Q9NWZ3-1 152 n/a n/a n/a n/a n/a n/a n/a n/a n/a YES25–29
IRAK4 Q9NWZ3-1 186 1,00 1.53E-10 1 S NVTNNFDERPIS(1)VGGNK 12 3 12,67 20,97 NO
IRAK4 Q9NWZ3-1 208 0,94 4.64E-06 1 T GYVNNT(0.937)T(0.063)VAVK 6 2 27,17 n/a YES (T208)
29
IRAK4 Q9NWZ3-1 345 0,89 1.81E-13 1 T FAQT(0.021)VMT(0.887)S(0.092)R 7 2 -0,71 0,95
YES 
(T345)29,30,32–36
Table 1. IRAK1, 2 and 4-related phospho-peptides. THP-1 macrophages previously labeled with stable isotopes 
were treated with Pam2 (5 μM) for 30 min, lysates prepared and the containing phospho-peptides analyzed by 
Mass spectrometry (see Methods). A single discovery/screening experiment was done. When sites were also 
listed on https://www.phosphosite.org this was also indicated below with residue numbering given in brackets.
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of whole blood from healthy donors with R848 resulted in robust induction of IL6 and CXCL10 mRNA, albeit 
with high inter-individual variation. Although the effects were moderate and differed between donors, the appli-
cation of BI2536 led to a dose-dependent reduction in both CXCL10 and IL6 mRNA levels in 2/3 of the donors, in 
some instances at an inhibitor concentration as low as 1 nM (Fig. 4a). BI6272 (Fig. 4b) and GSK461364 (Fig. 4c) 
were only analyzed in two donors, donor 2 and 3. Here donor 3 showed an inhibition of cytokine induction 
for both PLK inhibitors. Donor 2 remained refractory to all inhibitor treatments. Of note, PLK1 inhibitors did 
not affect another important innate immune signaling machinery, the NLRP3 inflammasome42: this was evident 
when THP-1 cells were treated with PMA and Nigericin, which triggers IL-1β release in these cells43. Conversely 
to a Bruton’s Tyrosine Kinase (BTK) inhibitor44, PLK inhibitors BI2536, BI6272 and GSK461364 did not block 
IL-1β release (Fig. 4d) which is regulated transcriptionally by PMA or TLR ligand, and maturation via the NLRP3 
inflammasome45. Cellular toxicity upon PLK1 inhibition was not observed (Fig. 4e). Although further donors will 
therefore need to be assessed, our results thus suggest a putative contribution of PLKs to TLR-dependent cytokine 
responses in certain donors.
Discussion
Over the last decades there has been much interest in exploring PLKs as targets in cancer therapy14. The data cur-
rently available suggests PLK inhibitors are efficacious in patients. This has been mainly attributed to the effects PLKs 
have on tumor cells themselves, i.e. the blocking of cell division. On the other hand, the effect of PLK inhibition on 
non-transformed cells has so far received little attention. Chevrier et al. recently proposed a role for murine PLKs in 
antiviral TLR signaling, posing the question whether PLK inhibition in humans might compromise innate immune 
defenses. If so, this should best be anticipated during phase III trials or later clinical use of PLK inhibitors. However, 
this previous study only focused on murine primary cells and cell lines and all other data in the human system have 
only been gleaned from transformed cells in which PLKs are likely to be regulated differently. Our observations in 
Figure 2. TLR stimulation induces PLK2 and 3 mRNA expression. Whole blood was treated with R848 or 
LPS at the indicated concentrations and for 2 or 6 h. Subsequently, total RNA was isolated, genomic DNA 
digested, reverse-transcribed and used in quantitative real-time PCR for the indicated PLKs relative to the TBP 
housekeeping gene. Four donors were assayed in triplicates. Biological means +/− SEM are shown.
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human primary whole blood, a highly physiological system for assessing immune activity, suggest that PLK inhibi-
tors may interfere with TLR-mediated cytokine production in certain subjects. Specifically and in keeping with the 
data by Chevrier et al., CXCL10 expression was reduced by PLK inhibition in response to TLR agonists10. Generally, 
a sufficient cytokine response is required for efficient immune cell recruitment to sites of infection and the mount-
ing of an adaptive immune response. Thus, PLK inhibition in patients may entail immunosuppression which is 
a phenomenon observed for many chemotherapeutic drugs, e.g. inhibitors of BTK, a signaling molecule acting 
downstream of B cell receptor and TLR signaling pathways46,47 which we recently found to be a direct regulator of 
the NLRP3 inflammasome44. Our data suggest that PLK inhibitors may compromise innate immunity, potentially 
via a direct effect on TLR signal transduction. Mechanistically, the suppression of PLK kinase activity may have a 
negative impact on phosphorylation events that promote signaling. At this point we can only speculate whether 
this will directly affect IRAKs or other pathway members and whether this occurs by PLKs being associated with 
Figure 3. PLK1 is phosphorylated in primary immune cells upon TLR stimulation. Freshly drawn whole blood 
was treated with R848 or left untreated for 10 min before erythrocytes were lysed, cells fixed, permeabilized and 
stained using anti-phospho-PLK1, -p38, -ERK1/2 or –p65. Gates were set to distinguish monocytes, peripheral 
blood lymphocytes (PBL) and PMN as shown in Fig. S1. Event # are given as indicated. In (a) one representative 
donor is shown, in (b) data from 2–3 donors are summarized. Each dot represents one donor. Differences were 
not statistically significant by one-way ANOVA with Sidak correction for multiple testing due to donor-to-
donor variations and the low number of donors.
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IRAKs either constitutively or only upon TLR signaling. Apart from a role as kinases, it is conceivable that PLK 
operate as scaffolds that reinforce interactions in post-receptor signaling. The effect of different TLR agonists on 
PLK1 phosphorylation, the inhibition conferred by PLK blockers, and the occurrence of PBMs in several IRAKs 
kinases would support the notion that PLKs connect and potentially operate on components of the Myddosome, 
where TLR pathways converge6. IRAKs and PLKs both were shown to separately interact with the prolyl-isomerase 
PIN121,48, which is also a PLK substrate. A direct interaction or substrate-kinase relationship between endogenously 
expressed IRAKs and PLKs has, however, yet to be demonstrated are significant limitations of this study. Since 
Figure 4. PLK inhibitors BI2536 and BI6272 donor-independently modulate TLR- but not NLRP3 
inflammasome-dependent cytokine responses. Freshly drawn whole blood was treated with 5 µg/ml R848 in the 
presence or absence of the indicated concentrations of BI2536 (a), BI6272 (b) or GSK461364 (c), respectively, 
for 3 h or left unstimulated. Subsequently, total RNA was isolated, genomic DNA digested, reverse-transcribed 
and used in quantitative real-time PCR for IL6 and CXCL10 mRNA relative to TBP. Each sample was measured 
in triplicates and individual symbols represent the mean for each donor coded by symbol type and color. 
The effects of inhibition were tested with reference to R848 + DMSO control using an unpaired two-tailed 
t-test. Technical triplicates that were statistically significantly (p < 0.05) higher or lower than the donor’s 
R848 + DMSO are marked by *. A combined statistical analysis did not yield significant differences due to 
high inter-individual variation. (d) ELISA analysis of IL-1ß in supernatants from PMA-differentiated THP-1 
cells treated for 1 h with the indicated PLK1 inhibitors and then stimulated with the NLRP3 agonist, nigericin. 
(e) Cell viability using CCK8 reagent normalized to DMSO control. In D and E data are representative of two 
independent experiments.
8Scientific RepoRtS |         (2019) 9:13168  | https://doi.org/10.1038/s41598-019-49017-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
co-overexpression and co-immunoprecipitation in transformed cells, e.g. in HEK293T cells may be confounded 
by overexpression artefacts, absence of endogenous signaling events or repetitive cell cycling, we attempted to 
co-immuno-precipitate PLKs and IRAKs from primary monocytes. Unfortunately, this failed in our hands due 
to the unavailability of specific PLK antibodies to endogenous PLKs Thus further mechanistic work thus remains 
clearly warranted in future, e.g. studying the effect of the newly identified PBM phospho-sites in IRAK2 and IRAK4 
on PLK interactions and TLR post-receptor signaling: Discovering both the kinase(s) phosphorylating the PBMs in 
IRAKs, as well as substrated phosphorylated by PLKs after recruitment via these phosphorylated PBMs would be 
interesting next steps. That IRAK phosphorylation may critically regulate TLR post-receptor signaling at the level 
of the Myddosome complex6,49 was recently shown by our groups for serine 8 in IRAK422. In depth studies of the 
novel IRAK phospho- and PBM sites identified here may thus provide further insights into how TLR signaling is 
regulated and how PLK inhibitors may interfere with the TLR arm of innate immunity. Elucidating the latter appears 
mandatory to anticipate the potential impact on innate immunity in patients undergoing PLK inhibitor treatments. 
Although the number of donors analyzed for the inhibitor study was very limited and needs to be expanded (ideally 
to healthy donors and cancer patients) before drawing more generally applicable conclusions, our results suggest that 
suppression of TLR signaling could be an unwanted side-effect for the use of PLK inhibitors in humans, they at the 
same time open up the possibility that PLK inhibitors may offer therapeutic opportunities under disease conditions 
where excessive TLR-driven cytokine production is pathophysiological, for example in rheumatoid arthritis, psori-
asis or lung inflammation Further investigations in experimental in vivo models or monitoring the effects on TLR 
signaling in clinical studies are clearly warranted.
Methods
Reagents and cells. Reagents were from Sigma unless otherwise stated. The following TLR ligands were 
used: Pam2CSK4 (Axxora or Invivogen), poly(I:C) (Sigma), R848 (Invivogen), LPS (Invivogen). Cellular viability 
was determined using the CCK8 reagent (Dojindo) according to the manufacturer’s instructions.
IRAK2-HA expression and purification. Human IRAK2 with StrepHA tag50,51 was expressed from HEK 
293 FlipIn TRex as outlined in supplemental methods. In brief, IRAK2-StrepHA-containing lysates were loaded 
onto a Strep-tactin Sepharose (IBA) column, washed 3 times and eluted with Buffer E (100 mM Tris, pH 8.0; 
150 mM NaCl, 1 mM EDTA, 2.5 mM des-thiobiotin). Elution fractions were checked on silver stained gel for 
protein yield and purity (verified by SDS-PAGE followed by standard silver staining) and pooled for MS/MS.
Mass spectrometry analysis of IRAK2. Protein samples were dissolved in denaturation buffer (DB), 
reduced and alkylated before LysC (Waco) digestion. Phospho-peptides were enriched using TiO2 beads, sub-
jected to liquid chromatography on an EasyLC nano-HPLC (Proxeon Biosystems) with a nano-HPLC column 
with C18 spheres (Dr. Maisch) and MS/MS analysis performed on a LTQ-Orbitrap XL mass spectrometer 
(Thermo Fisher Scientific). Further details are provided in Supplemental Methods.
IRAK4 expression and purification. Human IRAK4 was cloned into the pETG30 vector and expressed 
in BL21 Codon Plus cells as previously described22,49. Briefly, IRAK4 was expressed as a GST fusion protein and 
Prescission protease was used to cleave it from its fusion partner. It was thereafter purified by both ion exchange 
and size exclusion chromatography.
Dimethyl-labeling of THP-1 cells and global phosho-proteome mass spectrometry analysis. 
THP-1 cells (Invivogen) were primed with PMA (300 ng/mL, InvivoGen) overnight and then stimulated with PBS 
or 5 µM Pam2 for 30 minutes. Dimethyl-labeling of equal amounts of lysate, sample workup, MS acquisition, peak 
annotation and database searches was done as described in Supplemental Methods. Data were deposited in the 
PRIDE database (identifier PXD007542).
NLRP3 inflammasome analysis. THP-1 cells were primed with PMA (100 ng/mL, InvivoGen) overnight, 
incubated with PLK1 inhibitors BI 2536, BI 6727, GSK461364 (Selleckchem, at 1, 0.01 or 0.001 μM) for 1 hour, 
and then stimulated with 15 µM nigericin (InvivoGen) for 1 h. IL-1ß levels in supernatants were determined with 
half-area plates by using ELISA (BioLegend) with quadruplicate points on a standard plate reader. Cell viability 
was assayed using Cell Counting Kit-8 (CCK-8, Dojindo Laboratories) following the manufacturer’s instructions. 
The absorbance at 450 nm was measured using a microplate reader.
Whole blood analysis of cytokine transcription and phospho-flow. Heparinized whole blood was 
drawn from healthy volunteers at the Department of Immunology, Tübingen upon written informed consent and 
according to a study protocol approved by the ethics committee of the Medical Faculty of Tübingen University, 
Germany. Phospho-flow analysis Cytokine transcription in whole blood was done as described before40,50 and 
detailed in Supplemental Methods.
Real-time pcR. mRNA was isolated (cell lines: RNeasy Mini Kit; whole blood: QIAamp RNA Blood Mini 
Kit; Qiagen) and transcribed to cDNA (High Capacity RNA-to-cDNA Kit; LifeTechnologies). The expres-
sion IL6 (Hs00985639_m1) and CXCL10 (Hs01124251_g1) was studied using the indicated TaqMan Gene 
Expression Assays (LifeTechnologies). Data were normalized to the housekeeping gene TBP (Hs00427621_m1; 
LifeTechnologies). PLK1-4 primers for SYBR Green qPCR are listed in Supplementary Methods. The samples 
were analyzed on a real time cycler (Applied Biosystems; 7500 fast).
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Statistical analysis. For functional analyses, data was analyzed using Excel 2010 (Microsoft) and 
GraphPad Prism 5.0 (GraphPad Software, Inc.). p-values were determined using an unpaired t test, as indicated. 
p-values < 0.05 were generally considered statistically significant and are denoted by * throughout.
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